These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 27721983)

  • 21. Altered expression of cellular proliferation, apoptosis and the cell cycle-related genes in lung cancer cells with acquired resistance to EGFR tyrosine kinase inhibitors.
    Lee TG; Jeong EH; Min IJ; Kim SY; Kim HR; Kim CH
    Oncol Lett; 2017 Aug; 14(2):2191-2197. PubMed ID: 28781659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
    Naumov GN; Nilsson MB; Cascone T; Briggs A; Straume O; Akslen LA; Lifshits E; Byers LA; Xu L; Wu HK; Jänne P; Kobayashi S; Halmos B; Tenen D; Tang XM; Engelman J; Yeap B; Folkman J; Johnson BE; Heymach JV
    Clin Cancer Res; 2009 May; 15(10):3484-94. PubMed ID: 19447865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.
    Ma C; Wei S; Song Y
    J Thorac Dis; 2011 Mar; 3(1):10-8. PubMed ID: 22263058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.
    Hwang KE; Kwon SJ; Kim YS; Park DS; Kim BR; Yoon KH; Jeong ET; Kim HR
    Exp Cell Res; 2014 May; 323(2):288-96. PubMed ID: 24631288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation.
    Karachaliou N; Gimenez-Capitan A; Drozdowskyj A; Viteri S; Moran T; Carcereny E; Massuti B; Vergnenegre A; de Marinis F; Molina MA; Teixido C; Rosell R
    Transl Lung Cancer Res; 2014 Jun; 3(3):122-30. PubMed ID: 25806291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.
    Zhang Q; Ke E; Niu F; Deng W; Chen Z; Xu C; Zhang X; Zhao N; Su J; Yang J; Yan H; Wu Y; Zhou Q
    Oncotarget; 2017 Jan; 8(3):4994-5002. PubMed ID: 27999211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comparison of epidermal growth factor receptor (EGFR) gene T790M mutation by droplet digital PCR and Super-ARMS PCR in plasma ctDNA samples of non-small cell lung cancer patients with the resistance to EGFR-tyrosine kinase inhibitor].
    Cao ZY; Wu W; Hou LK; Zhang W; Gao CX; Wu CY; Zhang LP
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):910-914. PubMed ID: 30522170
    [No Abstract]   [Full Text] [Related]  

  • 28. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
    Lee CK; Kim S; Lee JS; Lee JE; Kim SM; Yang IS; Kim HR; Lee JH; Kim S; Cho BC
    Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation.
    Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Hida T; Yatabe Y
    Clin Lung Cancer; 2017 Nov; 18(6):698-705.e2. PubMed ID: 28596108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
    Lee Y; Wang Y; James M; Jeong JH; You M
    Mol Carcinog; 2016 May; 55(5):991-1001. PubMed ID: 26052929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation.
    Rho JK; Choi YJ; Jeon BS; Choi SJ; Cheon GJ; Woo SK; Kim HR; Kim CH; Choi CM; Lee JC
    Mol Cancer Ther; 2010 Dec; 9(12):3233-43. PubMed ID: 21159609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
    Pao W; Miller VA; Politi KA; Riely GJ; Somwar R; Zakowski MF; Kris MG; Varmus H
    PLoS Med; 2005 Mar; 2(3):e73. PubMed ID: 15737014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy.
    Moreira-Leite FF; Harrison LR; Mironov A; Roberts RA; Dive C
    J Thorac Oncol; 2010 Jun; 5(6):765-77. PubMed ID: 20421816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
    Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
    Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
    Qu G; Liu C; Sun B; Zhou C; Zhang Z; Wang P
    Oncol Rep; 2014 Jul; 32(1):341-7. PubMed ID: 24842595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
    Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
    Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib.
    Chmielecki J; Pietanza MC; Aftab D; Shen R; Zhao Z; Chen X; Hutchinson K; Viale A; Kris MG; Stout T; Miller V; Rizvi N; Pao W
    J Thorac Oncol; 2012 Feb; 7(2):434-42. PubMed ID: 22173702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.
    Suda K; Murakami I; Katayama T; Tomizawa K; Osada H; Sekido Y; Maehara Y; Yatabe Y; Mitsudomi T
    Clin Cancer Res; 2010 Nov; 16(22):5489-98. PubMed ID: 21062933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular mechanism of acquired drug resistance in the EGFR-TKI resistant cell line HCC827-TR.
    Yu T; Xia Q; Gong T; Wang J; Zhong D
    Thorac Cancer; 2020 May; 11(5):1129-1138. PubMed ID: 32163227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
    Furugaki K; Fukumura J; Iwai T; Yorozu K; Kurasawa M; Yanagisawa M; Moriya Y; Yamamoto K; Suda K; Mizuuchi H; Mitsudomi T; Harada N
    Int J Cancer; 2016 Feb; 138(4):1024-32. PubMed ID: 26370161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.